ClinicalTrials.Veeva

Menu

Changes Associated With H. Pylori and Gastric Carcinogenesis (IIT H pylori)

Weill Cornell Medicine (WCM) logo

Weill Cornell Medicine (WCM)

Status

Enrolling

Conditions

Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

Treatments

Procedure: Endoscopy tissue collection

Study type

Observational

Funder types

Other

Identifiers

NCT02164409
1203012274

Details and patient eligibility

About

This is a research study for patients who currently have or previously had an H. pylori infection or who have gastric or esophageal cancer and who plan to undergo an endoscopy as part of their care. The purpose of this study is to find out how and why H. pylori infections can cause progression to gastric cancer and if it's possible for intervention prior to this progression.

Full description

H. pylori infection is a prevalent environmental cause of gastric cancer. The molecular mechanisms of carcinogenesis due to H. pylori remain unexplained and consequences of infection are variable and unpredictable. The aim of this research is to examine the RNA transcriptome of gastric cancer mucosa (gastric mucosa is the mucus membrane of the stomach), in patients with H. pylori infection and examine the spectrum of disease associated with infection. We will also examine bacterial content of samples to pinpoint the specific H. pylori strain(s) and the stomach microbial profile to correlate with the gastric mucosal transcriptome and predisposition of gastric cancer. Patients with prior or current active H. pylori infection who are planning to under endoscopic evaluation will be eligible for participation. From these patients, we plan to take up to four additional biopsies from each area of stomach already being sampled.

The biopsies will be used for next-generation RNA and DNA sequencing and novel bioinformatics analyses. The analysis will be performed at Weill Cornell Medical College by Doron Betel, PhD. The sequencing will be performed in the Epigenetics Core laboratory under the supervision of Doron Betel, who will be working closely with the principal investigator, Manish A. Shah, M.D. Examination of the genetic impact of H. pylori infection in patients may expose genetic factors that influence gastric cancer carcinogenesis and give deeper insight into molecular pathways that serve as candidate biomarkers for gastric cancer carcinogenesis. Our goal is to distinguish patients with chronic H. pylori infection who are at risk of subsequently developing gastric cancer from the vast majority of patients with H. pylori infection who do not develop malignancy.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patient must be 18 years or older
  • Patient must have active or prior H. pylori infection, or have been treated for H.pylori infection in the past, as assessed by ELISA (not applicable for the subset of patient controls) or have gastric or esophageal cancer or have Barrett's Esophagus
  • Patients must be eligible for and are planning to undergo a routine upper endoscopy and tissue biopsy
  • Patients must sign informed consent

Exclusion criteria

  • Prior history of upper GI bleed (within 3 months)
  • Bleeding disorder or coagulopathy
  • Recent stroke or myocardial infarction (within 3 months)

Trial design

120 participants in 2 patient groups

Patient
Description:
Subjects for this study will be either H. pylori positive with an active infection, cleared of an H. pylori infection or be both H. pylori antibody positive and have a malignancy of the gastrointestinal tract, specifically gastric adenocarcinoma.
Treatment:
Procedure: Endoscopy tissue collection
Control
Description:
A small subset of patients without H. pylori infection will be enrolled as well (n=30) to serve as a control group.
Treatment:
Procedure: Endoscopy tissue collection

Trial contacts and locations

1

Loading...

Central trial contact

Casey Owens, MPH; June Greenberg, BSN,RN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems